The MarketVue®: Generalized Pustular Psoriasis market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Spesolimab potential approval as an acute and maintenance therapy would avoid many of the challenges associated with prescribing off-label therapies to treat GPP and could offer dermatologists the opportunity to establish a continuity of care of both flare control and subsequent long-term flare prevention utilizing the same therapy.
Dermatologist, U.S.: 'An ideal drug would be something that’s safe, gets acute flare under control quickly, and something that gives a sustained response that we can administer outpatient to hopefully keep their disease under control on a day-to-day basis, so minimal to little skin involvement and also prevention of the acute flares.'
Beyond spesolimab, there remains little in the pipeline for GPP. Like BI, AnaptysBio has an IL-36 inhibitor, imsidolimab, in clinical trials for both flare control and prevention, but will seek to outlicense the drug before approval. This development could potentially delay imsidolimab’s entry to market, but even with approvals for both spesolimab and imsidolimab, some unmet needs may be left unaddressed for those that do not respond well to IL-36 inhibitors.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
- Disease overview: Review the disease pathophysiology and potential druggable targets
- Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
- Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
- Unmet needs: Identify opportunities to address treatment or disease management gaps
- Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
- Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Generalized Pustular Psoriasis report is supported by 4 qualitative interviews with key opinion leaders, a quantitative survey with 27 physicians and secondary research.Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom).Key companies mentioned:
- Boehringer Ingelheim
- AnaptysBio
- Shanghai Huaota Biopharmaceutical
Key drugs mentioned:
- Calcipotriene
- Tacrolimus
- Acitretin
- Methotrexate
- Cyclosporine
- Apremilast (Otezla)
- Infliximab (Remicade)
- Adalimumab (Humira)
- Secukinumab (Cosentyx)
- Ixekizumab (Taltz)
- Brodalumab (Siliq)
- Guselkumab (Tremfya)
- Risankizumab (Skyrizi)
- Ustekinumab (Stelara)
- Spesolimab (Spevigo)
- Canakinumab (Ilaris)
- Gevokizumab
- Anakinra (Kineret)
- Etanercept (Enbrel)
- Imsidolimab
- HB0034
Key takeaways from the report:
Before the approval of Spevigo, the treatment landscape for GPP consisted solely of off-label therapies approved for psoriasis, including:
- Topical therapies
- Cyclosporine
- Methotrexate
- Biologics used to treat psoriasis (e.g., anti-TNF-α, IL-1, IL-17, etc.)
Spesolimab potential approval as an acute and maintenance therapy would avoid many of the challenges associated with prescribing off-label therapies to treat GPP and could offer dermatologists the opportunity to establish a continuity of care of both flare control and subsequent long-term flare prevention utilizing the same therapy.
Dermatologist, U.S.: 'An ideal drug would be something that’s safe, gets acute flare under control quickly, and something that gives a sustained response that we can administer outpatient to hopefully keep their disease under control on a day-to-day basis, so minimal to little skin involvement and also prevention of the acute flares.'
Beyond spesolimab, there remains little in the pipeline for GPP. Like BI, AnaptysBio has an IL-36 inhibitor, imsidolimab, in clinical trials for both flare control and prevention, but will seek to outlicense the drug before approval. This development could potentially delay imsidolimab’s entry to market, but even with approvals for both spesolimab and imsidolimab, some unmet needs may be left unaddressed for those that do not respond well to IL-36 inhibitors.
Table of Contents
1. DISEASE OVERVIEW- A recurrent inflammatory disorder causing pustules across the skin’s surface
- Figure 1.1. Common triggers of GPP flares
- Figure 1.2. Complications related to GPP
- Figure 1.3. Frequency and management of GPP symptom flares/exacerbations
- Disease definition
- Figure 2.1. G6 prevalent cases of GPP by region
- Table 2.1. Prevalent and drug-treated populations of GPP in the U.S. and EU5
- Overview
- Figure 3.1. Treatment goals for GPP
- Figure 3.2. Current treatment patient share
- TNF-alpha inhibitors and IL-17 inhibitors are the most commonly used biologics in GPP
- Figure 3.3. Dermatologist-reported biologic use in GPP patients by drug class
- Figure 3.4. Preferred second-line biologic classes among surveyed dermatologists
- Figure 3.5. Percentage of GPP patients who fail first-line biologic therapy
- Dermatologists choose biologics that are effective in psoriasis
- Treatment decisions for GPP
- Figure 3.6 Treatment algorithm for GPP
- Dermatologists tend to view GPP as a form of psoriasis
- GPP treatment options are moderately effective
- Table 3.1. Upside and downsides of currently GPP treatments
- Off-label GPP treatment options have their limitations
- An IL-36 biologic is the first approved therapy for GPP
- Figure 3.7. Results of Ph 2 Trial of a Single IV dose of Spesolimab in Patients with an Acute GPP Flare
- Figure 3.8. Prior use of IV spesolimab (Spevigo) for the treatment of GPP flare
- Figure 3.9. Dermatologists’ reported efficacy of IV spesolimab in treating GPP flare
- Interviewed dermatologists who have prescribed Spevigo report patients have responded well
- Figure 3.10. Dermatologists’ likelihood of prescribing spesolimab as a SC maintenance therapy if approved
- Dermatologists consider efficacy and fast onset of action as top attributes for GPP treatment agents
- Figure 3.11. Percentage of dermatologists selecting attribute among their top three most important for treatment selection in GPP
- GPP has a severe impact on psycho-social aspects and the quality of life of patients
- Figure 3.12. Dermatologists’ rating of the impact of GPP on patients
- Key treatment dynamics that shape disease management and drug use in GPP
- Table 3.2. Must-know GPP treatment dynamics for now and the future
- Figure 3.13. Percentage of patients with unsatisfactory outcomes with current GPP treatments
- The GPP pipeline is limited to IL-36R inhibitors
- Figure 3.14. Important dynamics of GPP market evolution
- Overview
- Figure 4.1. Top unmet needs in GPP
- Figure 4.2. Dermatologist-reported unmet needs in GPP
- Physician perspectives on unmet needs in GPP
- Overview
- Figure 5.1. Percent of U.S. dermatologists rating GPP therapy target as “promising”
- The ongoing IL-36 trial designs indicate intended treatment goals
- Table 5.1. Comparison of ongoing trials of anti-IL-36R antibodies in GPP
- Critical spesolimab data will arrive in Q4 of 2022
- Figure 5.3. Key dates for the IL-36 therapies
- Figure 5.4. Selected results from phase 2 GALLOP trial of imsidolimab in adult patients with active GPP
- Figure 5.5. Trial design of imsidolimab’s Phase 3 GEMINI program in GPP
- Spesolimab may secure another critical corner of the market if approved for maintenance therapy
- Overview
- Table 6.1. Current therapy pricing, U.S. 2023
- Patient access considerations based on the recent approval of Spevigo
- Figure 6.1. Resources offered by BI to help facilitate Spevigo patient access
- Primary market research approach
- Epidemiology methodology
- Value and access methodology
Samples
LOADING...
Companies Mentioned
- Boehringer Ingelheim
- AnaptysBio
- Shanghai Huaota Biopharmaceutical
